Formulation and Optimization of Candesartan Cilexetil Nano Lipid Carrier: In Vitro and In Vivo Evaluation

Author(s): Anjan Paudel, Ameeduzzafar, Syed Sarim Imam, Mohd Fazil, Shahroz Khan, Abdul Hafeez, Farhan Jalees Ahmad, Asgar Ali*

Journal Name: Current Drug Delivery

Volume 14 , Issue 7 , 2017

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Purpose: The objective of this study was to formulate and optimize Candesartan Cilexetil (CC) loaded nanostructured lipid carriers (NLCs) for enhanced oral bioavailability.

Method: Glycerol monostearate (GMS), Oleic acid, Tween 80 and Span 40 were selected as a solid lipid, liquid lipid, surfactant and co- surfactant, respectively. The CC-NLCs were prepared by hot emulsion probe sonication technique and optimized using experimental design approach. The formulated CC-NLCs were evaluated for various physicochemical parameters and further optimized formulation (CC-NLC-Opt) was assessed for in vivo pharmacokinetic and pharmacodynamic activity.

Results: The optimized formulation (CC-NLC-Opt) showed particle size (183.5±5.89nm), PDI (0.228±0.13), zeta potential (-28.2±0.99mV), and entrapment efficiency (88.9±3.69%). The comparative in vitro release study revealed that CC-NLC-Opt showed significantly better (p<0.05) release and enhanced permeation as compared to CC-suspension. The in vivo pharmacokinetic study gave many folds increase in oral bioavailability than CC suspension, which was further confirmed by antihypertensive activity in a murine model.

Conclusion: Thus, the results of ex vivo permeation, pharmacokinetic study and pharmacodynamics study suggest the potential of CC-NLCs for improved oral delivery.

Keywords: Antihypertensive activity, bioavailability study, formulation design, candesartan cilexetil, lipid formulation, nanoparticle.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 16 October, 2017
Page: [1005 - 1015]
Pages: 11
DOI: 10.2174/1567201813666161230141717
Price: $65

Article Metrics

PDF: 19